Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Curelab Oncology Inc. has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is under the review of examiner CESARE, JOSEPH DAVID, who is the busiest examiner for the company with 1 pending action. The portfolio is concentrated in 1 distinct examiner and 1 distinct art unit. For a practitioner, this means that the success of the company's current patent efforts depends on the interpretation of a single examiner. No other examiners or units are currently providing feedback on the company's applications.
The existence of 1 pending office action indicates a very targeted approach to patenting. Since the matter is located in 1 distinct art unit, the practitioner only needs to navigate the specific requirements of that administrative group. CESARE, JOSEPH DAVID is the sole examiner currently reviewing the company's pending work, so understanding their specific procedural preferences is essential. The Biotechnology & Pharmaceuticals technology area indicates the subject matter is likely related to oncological or biological hardware. With 1 distinct examiner and 1 distinct art unit, the company's current prosecution profile is highly centralized.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CESARE, JOSEPH DAVID | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18651691 | Methods and Compositions Relating to p62/SQSTM1 for the Treatment and Prevention of Inflammation-Associated Diseases | CESARE, JOSEPH DAVID | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18651691 | Methods and Compositions Relating to p62/SQSTM1 for the Treatment and Prevention of Inflammation-Associated Diseases | CESARE, JOSEPH DAVID | 1675 | §103§112DP | Non-Final OA | — | Pending | Apr 30, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCurelab Oncology Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Joseph David Cesare has the most, with 1 of Curelab Oncology Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.